Strobel, Oliver

Optimizing the outcomes of pancreatic cancer surgery

Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 943

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Baumann, D., Hägele, T., Mochayedi, J., Drebant, J., Vent, C., Blobner, S., Noll, J. H., Nickel, I., Schumacher, C., Boos, S. L., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 76

Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability

Jäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 69

Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial

Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., et al. (2025) · Langenbeck's Archives of Surgery

Cancer, Stress, Anesthesia, and Immune ResponsePancreatic and Hepatic Oncology Research

Cited by 15

Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial

Hüttner, F. J., Rooman, I., Bouche, G., Knebel, P., Hüsing, J., Mihaljevic, A. L., Hackert, T., Strobel, O., Büchler, M. W., & Diener, M. K. (2020) · BMJ Open

Cancer, Stress, Anesthesia, and Immune ResponsePancreatic and Hepatic Oncology Research

Cited by 13